Home » Stocks » Neon Therapeutics

Neon Therapeutics, Inc. (NTGN)

May 6, 2020 - NTGN was delisted (reason: acquired by BNTX)
Stock Price: $3.07 USD 0.00 (0.00%)
Updated May 6, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 88.92M
Revenue (ttm) n/a
Net Income (ttm) -75.35M
Shares Out 28.96M
EPS (ttm) -2.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 6, 2020
Last Price $3.07
Previous Close $3.07
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.92 - 3.09
Day's Volume 3,609,767
52-Week Range 0.88 - 6.15

More Stats

Market Cap 88.92M
Enterprise Value 81.36M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.96M
Float n/a
EPS (basic) -2.68
EPS (diluted) -2.68
FCF / Share -2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 743,908
Short Ratio 1.29
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.16
Revenue n/a
Operating Income -76.22M
Net Income -75.35M
Free Cash Flow -66.60M
Net Cash 7.56M
Net Cash / Share 0.26
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -70.63%
ROE -156.16%
ROIC -402.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

Current: $3.07
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-81.14-78.70-48.09-27.42
Net Income-79.78-76.93-47.54-27.43
Shares Outstanding27.8815.041.690.99
Earnings Per Share-2.86-5.54-34.32-30.72
Operating Cash Flow-73.41-63.43-41.28-24.16
Capital Expenditures-1.08-3.22-3.24-2.36
Free Cash Flow-74.50-66.65-44.52-26.51
Cash & Equivalents29.4010379.7388.49
Total Debt7.78---
Net Cash / Debt21.6110379.7388.49
Book Value29.42101-93.57-38.49
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neon Therapeutics, Inc.
Country United States
Employees 71

Stock Information

Ticker Symbol NTGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTGN
IPO Date June 27, 2018


Neon Therapeutics, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatment of cancers driven or mediated by RAS mutations. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.